OBJECTIVES: Identifying factors associated with mortality among acutely ill HIV-infected children presenting with advanced HIV disease may help clinicians optimize care for those at highest risk of death. DESIGN: Using data from a randomized controlled trial (NCT02063880), we determined baseline sociodemographic, clinical, and laboratory cofactors of mortality among HIV-infected children in Kenya. METHODS: We enrolled hospitalized, HIV-infected, antiretroviral therapy-naive children (0-12 years), initiated antiretroviral therapy, and followed up them for 6 months. We used Cox proportional hazards regression to estimate hazard ratios (HRs) for death and 95% confidence intervals (CIs). RESULTS: Of 181 enrolled children, 39 (22%) died. Common diagnoses at death were pneumonia or suspected pulmonary tuberculosis [23 (59%)] and gastroenteritis [7 (18%)]. Factors associated with mortality in univariate analysis included age <2 years [HR 3.08 (95% CI: 1.50 to 6.33)], orphaned or vulnerable child (OVC) [HR 2.05 (95% CI: 1.09 to 3.84)], weight-for-age Z score <-2 [HR 2.29 (95% CI: 1.05 to 5.00)], diagnosis of pneumonia with hypoxia [HR 5.25 (95% CI: 2.00 to 13.84)], oral thrush [HR 2.17 (95% CI: 1.15 to 4.09)], persistent diarrhea [HR 3.81 (95% CI: 1.89 to 7.69)], and higher log10 HIV-1 viral load [HR 2.16 (95% CI: 1.35 to 3.46)] (all P < 0.05). In multivariable analysis, age <2 years and OVC status remained significantly associated with mortality. CONCLUSIONS: Young age and OVC status independently predicted mortality. Hypoxic pneumonia, oral thrush, and persistent diarrhea are important clinical features that predict mortality. Strategies to enhance early diagnosis in children and improve hospital management of critically ill HIV-infected children are needed.
RCT Entities:
OBJECTIVES: Identifying factors associated with mortality among acutely ill HIV-infectedchildren presenting with advanced HIV disease may help clinicians optimize care for those at highest risk of death. DESIGN: Using data from a randomized controlled trial (NCT02063880), we determined baseline sociodemographic, clinical, and laboratory cofactors of mortality among HIV-infectedchildren in Kenya. METHODS: We enrolled hospitalized, HIV-infected, antiretroviral therapy-naive children (0-12 years), initiated antiretroviral therapy, and followed up them for 6 months. We used Cox proportional hazards regression to estimate hazard ratios (HRs) for death and 95% confidence intervals (CIs). RESULTS: Of 181 enrolled children, 39 (22%) died. Common diagnoses at death were pneumonia or suspected pulmonary tuberculosis [23 (59%)] and gastroenteritis [7 (18%)]. Factors associated with mortality in univariate analysis included age <2 years [HR 3.08 (95% CI: 1.50 to 6.33)], orphaned or vulnerable child (OVC) [HR 2.05 (95% CI: 1.09 to 3.84)], weight-for-age Z score <-2 [HR 2.29 (95% CI: 1.05 to 5.00)], diagnosis of pneumonia with hypoxia [HR 5.25 (95% CI: 2.00 to 13.84)], oral thrush [HR 2.17 (95% CI: 1.15 to 4.09)], persistent diarrhea [HR 3.81 (95% CI: 1.89 to 7.69)], and higher log10 HIV-1 viral load [HR 2.16 (95% CI: 1.35 to 3.46)] (all P < 0.05). In multivariable analysis, age <2 years and OVC status remained significantly associated with mortality. CONCLUSIONS: Young age and OVC status independently predicted mortality. Hypoxic pneumonia, oral thrush, and persistent diarrhea are important clinical features that predict mortality. Strategies to enhance early diagnosis in children and improve hospital management of critically ill HIV-infectedchildren are needed.
Authors: Patricia B Pavlinac; Grace C John-Stewart; Jaqueline M Naulikha; Frankline M Onchiri; Donna M Denno; Elizabeth A Odundo; Benson O Singa; Barbra A Richardson; Judd L Walson Journal: AIDS Date: 2014-09-24 Impact factor: 4.177
Authors: Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Ken Tapia; Evelyn Ngugi; Jennifer A Slyker; Barbra A Richardson; Grace C John-Stewart Journal: Pediatr Infect Dis J Date: 2012-07 Impact factor: 2.129
Authors: Carolyn Bolton-Moore; Mwangelwa Mubiana-Mbewe; Ronald A Cantrell; Namwinga Chintu; Elizabeth M Stringer; Benjamin H Chi; Moses Sinkala; Chipepo Kankasa; Craig M Wilson; Catherine M Wilfert; Albert Mwango; Jens Levy; Elaine J Abrams; Marc Bulterys; Jeffrey S A Stringer Journal: JAMA Date: 2007-10-24 Impact factor: 56.272
Authors: Nathan Ford; Zara Shubber; Graeme Meintjes; Beatriz Grinsztejn; Serge Eholie; Edward J Mills; Mary-Ann Davies; Marco Vitoria; Martina Penazzato; Sabin Nsanzimana; Lisa Frigati; Daniel O'Brien; Tom Ellman; Olawale Ajose; Alexandra Calmy; Meg Doherty Journal: Lancet HIV Date: 2015-08-11 Impact factor: 12.767
Authors: James Hakim; Victor Musiime; Alex J Szubert; Jane Mallewa; Abraham Siika; Clara Agutu; Simon Walker; Sarah L Pett; Mutsa Bwakura-Dangarembizi; Abbas Lugemwa; Symon Kaunda; Mercy Karoney; Godfrey Musoro; Sheila Kabahenda; Kusum Nathoo; Kathryn Maitland; Anna Griffiths; Margaret J Thomason; Cissy Kityo; Peter Mugyenyi; Andrew J Prendergast; A Sarah Walker; Diana M Gibb Journal: N Engl J Med Date: 2017-07-20 Impact factor: 91.245
Authors: Li Liu; Shefali Oza; Daniel Hogan; Jamie Perin; Igor Rudan; Joy E Lawn; Simon Cousens; Colin Mathers; Robert E Black Journal: Lancet Date: 2014-09-30 Impact factor: 79.321
Authors: Nitika Pant Pai; Samantha Wilkinson; Roni Deli-Houssein; Rohit Vijh; Caroline Vadnais; Tarannum Behlim; Marc Steben; Nora Engel; Tom Wong Journal: Point Care Date: 2015-09
Authors: James G Carlucci; Caroline De Schacht; Erin Graves; Purificación González; Magdalena Bravo; Zhihong Yu; Gustavo Amorim; Folasade Arinze; Wilson Silva; Jose A Tique; Maria F S Alvim; Beatriz Simione; Anibal N Fernando; C William Wester Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771